• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Survival analysis of a comprehensive treatment strategy for internal carotid artery blowout syndrome by nasopharyngeal carcinoma
CONCLUSION: The comprehensive treatment strategy for ICA-CBS of patients with NPC significantly reduced the mortality of asphyxia due to epistaxis, reduced the incidence of CBS during nasal endoscopy, and finally improved survival rate.PMID:37309715 | DOI:10.1002/hed.27393
Source: Cancer Control - June 13, 2023 Category: Cancer & Oncology Authors: Zhouyang Zhao Qinming Liao Yimei Yang Yue Ma Xiaomeng Lu Qianhui Qiu Fei Han Lijin Huang Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Studies: Low-Dose Aspirin May Not Prevent Initial Heart Attack, Stroke
Taking a low-dose aspirin every day has long been known to cut the chances of another heart attack, stroke or other heart problem in people who already have had one, but the risks don’t outweigh the benefits for most other folks, major new research finds. Although it’s been used for more than a century, aspirin’s value in many situations is still unclear. The latest studies are some of the largest and longest to test this pennies-a-day blood thinner in people who don’t yet have heart disease or a blood vessel-related problem. One found that aspirin did not help prevent first strokes or heart attacks...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 27, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch aspirin Source Type: news

A father ’s hope for his son’s life
Juan and Fredy in 2017. Juan was looking forward to having his son, Fredy, 14, finally come home to live with him. The teenager had been living under the care of his grandmother since he was a toddler. But on that long-awaited homecoming day, Juan was quickly jarred from feeling great joy to grave concern. “When I saw his face, one side looked very different from the other and his lip was swollen,” says Juan. “He admitted right away that his face had been hurting.” Juan remembered that the last time he’d seen his son — more than one year ago — Fredy’s face had looked slightly different then too. But whateve...
Source: Thrive, Children's Hospital Boston - April 12, 2017 Category: Pediatrics Authors: Kat J. McAlpine Tags: Diseases & Conditions Our Patients’ Stories Dr. Cameron Trenor Dr. Carolyn Rogers Dr. Darren Orbach Dr. Reza Rahbar Dr. Salim Afshar interventional radiology juvenile nasopharyngeal angiofibroma tumor Source Type: news

5 Scary Symptoms That Are Usually Harmless
SPECIAL FROM Next Avenue By Linda Melone After 50, aches, pains and the occasional muscle twinge become a fact of life. But some symptoms that may seem frightening or serious turn out to be far less than they appear. While you should always see a doctor if you experience something out of the ordinary, these signs generally are more smoke than fire: A Bloody Nose Nosebleeds can be particularly frightening due to the suddenness in which they occur and the sometimes large amount of blood involved. “People worry that it’s internal bleeding, but almost every time it’s not,” says Dr. Carlo Reyes, emergency room...
Source: Healthy Living - The Huffington Post - February 5, 2015 Category: Consumer Health News Source Type: news